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Background: Prostate cancer screening depends on a careful balance of benefits, in terms of reduced prostate
cancer mortality, and harms, in terms of overdiagnosis and overtreatment. We aimed to estimate the effect on
overdiagnosis of restricting prostate specific antigen (PSA) testing by age and baseline PSA.
Methods: Estimates of the effects of age on overdiagnosis were based on population based incidence data from
the US Surveillance, Epidemiology and End Results database. To investigate the relationship between PSA and
overdiagnosis, we used two separate cohorts subject to PSA testing in clinical trials (n = 1,577 and n = 1,197) and a
population-based cohort of Swedish men not subject to PSA-screening followed for 25 years (n = 1,162).
Results: If PSA testing had been restricted to younger men, the number of excess cases associated with the
introduction of PSA in the US would have been reduced by 85%, 68% and 42% for age cut-offs of 60, 65 and 70,
respectively. The risk that a man with screen-detected cancer at age 60 would not subsequently lead to prostate
cancer morbidity or mortality decreased exponentially as PSA approached conventional biopsy thresholds. For PSAs
below 1 ng/ml, the risk of a positive biopsy is 65 (95% CI 18.2, 72.9) times greater than subsequent prostate cancer
mortality.
Conclusions: Prostate cancer overdiagnosis has a strong relationship to age and PSA level. Restricting screening in
men over 60 to those with PSA above median (>1 ng/ml) and screening men over 70 only in selected
circumstances would importantly reduce overdiagnosis and change the ratio of benefits to harms of PSA-screening.
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Overdiagnosis is a critical problem in prostate cancer
screening. Men with screen-detected cancers are com-
monly subject to radical prostatectomy or radiotherapy,
leading to persistent urinary, sexual and bowel morbid-
ities. Such treatment is no benefit for cancers that would
never have become apparent in the absence of screening.
Overdiagnosis was one of the reasons why the United
States Preventive Services Task Force recommended
against prostate specific antigen (PSA) screening [1].* Correspondence: vickersa@mskcc.org
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2014Risk of overdiagnosis varies in predictable ways. For ex-
ample, a cancer diagnosis prompted by a PSA of 10 ng/ml
in a healthy man in his early fifties would otherwise very
likely be clinically diagnosed in his lifetime; conversely, a
man in his 80s with a PSA only slightly above biopsy
thresholds would most probably die of another cause be-
fore signs or symptoms led to diagnosis. Yet, there are re-
markably few data on the impact of age and PSA level on
overdiagnosis. Papers often report specific estimates of
overdiagnosis for PSA screening as a whole [2,3]. These
estimates are averages that may obscure dramatic varia-
tions in overdiagnosis risk.
We hypothesized that if we could identify factors that
increase the risk of overdiagnosis, appropriate changes
in screening practices could importantly shift the ratioLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ence of age and PSA on prostate cancer overdiagnosis.
Specifically, we sought to estimate the proportion of ex-
cess cases diagnosed in the US in the years after the
introduction of the PSA-test that would have been avoi-
ded had PSA screening been restricted to younger men.
We then sought to estimate the risk of biopsy detectable
cancer relative to the long-term risk of prostate cancer
morbidity at a given PSA for 60-year-old men, approxi-
mately the midpoint of the age range in many screen-
ing recommendations. Both excess incidence and ratio
of the risk of cancer morbidity compared to biopsy detect-
able cancer are correlates of overdiagnosis, rather than
direct estimates, and are useful primarily for comparison
between groups. We hypothesized that there would be
large differences in the number of excess cases by age
group and risk of cancer-related morbidity by baseline
PSA level.
Methods
To investigate the association between age and excess
incidence we used data from the Surveillance, Epide-
miology and End Results (SEER) database. SEER 9 data
derive from several geographic regions in the US, repre-
senting close to 10% of the US population. The PSA test
started to be widely used as a screening test in the late
1980s, and the incidence sharply increased after that point
[4]. We compared the observed incidence of prostate can-
cer between 1987 and 1995 with the predicted incidence
without PSA screening during that time. The cutoff year
of 1995 was chosen as it is often considered to constitute
when incidence began to stabilize [5] and when stage shift
was no longer observed in clinical practice [6]. As a sensi-
tivity analysis, we explored other end dates.
To predict what the incidence of prostate cancer would
have been without the introduction of PSA screening,
we assumed that changes in incidence between 1973
and 1986 would continue through 1995. For each year
in age, we created a linear regression model to predict the
incidence by year of diagnosis for 1987 to 1995 on the
basis of incidence 1973 to 1986. To estimate the num-
ber of excess cases for a given year and age, we simply
subtracted predicted from observed cancer diagnoses
and standardized to the entire US population. We then
smoothed estimates by age using locally-weighted scatter-
plot smoothing (lowess), which can be thought of in terms
of a moving average of the number of excess cases for
each year of age at diagnosis. We repeated our analyses as-
suming that incidence after 1987 would have been similar
to that for 1986 had PSA testing not been introduced.
This counterfactual is supported by at least one statistical
analysis of incidence trends [5].
Calculation of excess cases provides only an indirect
estimate of overdiagnosis. This is for several reasons.First, some excess cases within an age stratum would
not constitute overdiagnosis as a cancer might be clinic-
ally diagnosed subsequently. For instance, a man diag-
nosed by screening in his late 50s might present with
prostate cancer symptoms in his early 70s and, therefore,
would not be an overdiagnosed case. However, this effect
constitutes a bias against our hypothesis that a large pro-
portion of overdiagnosed cases occur in older men: more
of the excess cases in young men would eventually be
clinically diagnosed than those in older men simply be-
cause younger men live longer, providing more time for
the cancer to become apparent. Second, the distribution
of excess cases is partly a reflection of screening rates
within age groups. If there were more excess cases in,
say, men aged 70 to 75 compared to those aged 65 to
70, this may just reflect that more men in the older co-
hort are getting PSA tests. However, that has no bearing
on the practical effect of restricting screening in older
men. If most of the excess incidence is in older men,
then screening fewer older men will have a dispropor-
tionate effect on overdiagnosis, irrespective of the exact
mechanism underpinning the distribution of excess inci-
dence. Finally, a precise estimate of the exact proportion
of overdiagnoses in each age stratum is not the aim of
the paper. We aimed only to determine if a substantial
proportion of overdiagnoses were in older men; whether
that proportion is 30%, 50% or 80%, our conclusion would
be the same, namely that restricting screening among
older men would have a large impact on overdiagnosis.
To investigate the relationship between overdiagnosis
and PSA level, we used data from an unscreened rep-
resentative population of men in Malmö, Sweden, who
participated in the Malmö Preventive Program (MPP).
The study has been previously described [7,8]. In brief,
1,162 60-year-old men, constituting 71% of the eligible
population, gave blood in 1981 to 1982 and were fol-
lowed to age 85. Cancer diagnoses were obtained from
the Swedish cancer registry, with ascertainment of me-
tastasis and death predominately on the basis of case
notes. Using a case–control design, archived ethylenedi-
aminetetraacetic acid (EDTA) anti-coagulated blood
plasma samples from participants were thawed and ana-
lyzed using a method that has been demonstrated to give
results close to what a contemporaneous PSA test would
have measured [9]. The risk of clinical diagnosis (rates of
PSA screening were very low during the period of the
study), metastasis and mortality by age 85 for a given
PSA level were calculated as described previously [10].
The Malmo cohort was close to 100% Caucasian and
family history data were not available, hence neither race
nor family history was entered into the analysis.
We also obtained data from two randomized trial co-
horts that involved PSA testing, where patients were
subject to prostate biopsy mandated by study protocols:
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(PCPT) [11] and the screening arm of the European
Randomized Study of Screening for Prostate Cancer
(ERSPC) in Rotterdam [2]. All men in the ERSPC cohort
were referred to biopsy due to an elevated PSA at their
first PSA test (≥3 ng/ml) in 1993 to 1999; the PCPT co-
hort included men undergoing regular screening who
had at least one prior low PSA (<3 ng/ml) and who were
either biopsied ‘for cause’ (PSA elevated above 4 ng/ml
or suspicious digital rectal exam) or biopsied without in-
dication at the end of the trial (1995 to 2003) as part of
the study protocol. Both cohorts were restricted to men
close to 60 years old (defined as 55 to 65), with 1,577
participants from PCPT and 1,197 from ERSPC. We used
lowess methods to estimate the risk of biopsy-detectable
cancer for a given PSA level. All PSA levels were standard-
ized to the WHO calibration.
We divided the risk of cancer on biopsy from the
PCPT or ERSPC cohorts by the long-term risk of clinical
prostate cancer, metastasis and cancer-specific mortality
in MPP. All analyses were conducted using Stata 12.0
(Stata Corp., College Station, TX, USA). This study in-
volved reanalysis of fully deidentified data that had been
taken for other purposes and previously analyzed as part
of other research studies. Permission to use data from
PCPT and ERSPC was obtained from the appropriate
oversight entities. Data were analyzed under waivers
from the Memorial Sloan-Kettering Cancer Center in-
stitutional review board.
Results
Table 1 shows the number of excess cases separately by
age at diagnosis, with the results shown graphically in
Figure 1. It is clear that there is a strong association be-
tween age and excess cases with low frequency in youn-
ger men (fewer than 20,000 excess cases in ages 50 to
54) compared to older men (approaching 115,000 excess
cases for the 70 to 74 age group). As pointed out above,
an excess case does not necessarily imply overdiagnosis,
so the key analysis is the relative number of cases be-
tween groups rather than absolute numbers within eachTable 1 Estimated number of excess cases of prostate cancer
Age category Observed Predicted Excess cas
45 to 49 years 10,232 4,277 5,955
50 to 54 years 37,389 17,633 19,756
55 to 59 years 88,783 47,407 41,376
60 to 64 years 188,018 111,004 77,014
65 to 69 years 311,865 195,602 116,263
70 to 74 years 351,991 238,803 113,188
75 to 79 years 277,274 218,476 58,798
80 to 85+ years 261,895 246,002 15,893group. Table 1 shows the cumulative proportion of ex-
cess cases. This can be thought of in terms of the reduc-
tion in excess cases had screening been restricted to
younger men. If testing had not been available for men
60+, 65+, or 70+ years old, excess cases would have been
reduced by 85%, 68%, and 42%, respectively.
Our findings were not importantly changed in sensitiv-
ity analysis. There was little effect of assuming a stable
incidence in the absence of screening (for example, 47%
of cases diagnosed in men older than 70 years). When
the time period is extended out to the year 2000, the re-
lationship between age and excess cases is moderated,
with 78%, 58% and 35% of cases in men older than 60,
65 and 70 years. A possible explanation for this effect is
that men overdiagnosed in their 70s during the early
part of the 1990s are not at risk for overdiagnosis in
their 80s towards the end of the decade. As a final
sensitivity analysis, we changed the incidence at age
50 to 59 years old between 1987 to 1995 so that it
matched that reported in 2005 to 2009, keeping the
incidence at other ages unchanged. Even under this
very conservative assumption, the proportion of excess
cases in men 60, 65, and 70 years old was 68%, 54%, and
33%, respectively.
Table 2 gives absolute risk by PSA level at age 60 for
biopsy detectable cancer in the screened cohorts versus
that of clinical cancer events within 25 years in the un-
screened cohort. The long-term risk of metastasis and
cancer-specific death remains low at PSA levels below
age median (≤1 ng/ml) and increases much more rapidly
for PSAs >1 ng/ml compared to the risk of screen- or
clinically-detected cancer. For example, risk of death from
disease rises more than 10-fold between PSAs of 1 and 4 ng/
ml, compared to only about a 1.5-fold rise for the risk of a
positive biopsy. This relationship is shown in Table 3 and
Figure 2. Patients with PSA levels below common prostate
biopsy thresholds at age 60 have a much greater probability
of a positive biopsy than of dying from prostate cancer by
age 85. For example, at a PSA of 1 ng/ml, a 60-year-old man
is 29 times more likely to have a positive biopsy than to die
from cancer. This ratio rises rapidly to greater than 100 asdiagnosed between 1987 and 1995
es 95% confidence interval Cumulative proportion
5,803 to 6,106 1.3%
19,480 to 20,031 5.7%
40,977 to 41,774 15.0%
76,471 to 77,558 32.1%
115,596 to 116,930 58.1%
112,530 to 113,846 83.3%
58,324 to 59,273 96.5%
15,646 to 16,140 100%
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Figure 1 Number of excess prostate cancer cases by age at
diagnosis 1987 to 1995. The 95% confidence interval is extremely
narrow and is not shown here.
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3 ng/ml. Results for higher PSAs are fairly comparable
between men subject to repeat screening (PCPT) and
those undergoing an initial PSA test (ERSPC). The ra-
tio between risk of biopsy-detectable cancer and risk
of metastasis falls slightly more rapidly in the placebo-
treated controls of the PCPT cohort, likely because, in
intensively screened individuals, risk of a positive bi-
opsy does not importantly rise as PSA increases above
biopsy thresholds [12].
Across PSA levels, the risk of biopsy-detectable cancer
is similar to the risk of a clinical diagnosis of cancer
within 25 years. The ratio of these two risks ranges from
slightly above 2 for low PSAs to close to 1 for PSAs
above common biopsy thresholds, such as 4 ng/ml. We
assume that most men with elevated PSA at age 60 and
who subsequently develop prostate cancer would have
had a positive biopsy had they been biopsied at 60. If
such an assumption is correct, these results suggest thatTable 2 Absolute risk of biopsy detected cancer compared to
PSA (ng/ml) Clinical diagnosis Distant metastasis Cancer-specific
<1.0 4.5 (2.9, 6.1) 0.6 (<0.1, 1.2) 0.2 (<0.1, 0
0.5 3.8 (2.2, 5.4) 0.3 (0.1, 0.6) 0.1 (<0.1, 0
1.0 6.1 (5.0, 7.3) 1.2 (0.6, 1.7) 0.6 (0.2, 1
2.0 13.1 (11.2, 14.2) 4.6 (3.6, 5.1) 3.8 (2.9, 4
3.0 16.8 (15.3, 20.3) 6.6 (5.6, 8.4) 5.5 (4.8, 7
4.0 19.6 (17.8, 26.9) 8.6 (7.3, 12.4) 7.2 (6.1, 11
5.0 21.9 (19.6, 32.9) 10.3 (8.7, 16.4) 8.6 (7.1, 15
7.5 28.2 (24.0, 49.7) 14.9 (12.2, 27.2) 12.4 (10.0, 2
10.0 33.6 (27.9, 65.0) 19.1 (15.4, 37.4) 15.9 (12.4, 3
The data compare an unscreened Swedish cohort (MPP) with two screened cohorts
Data are given as percent risk with 95% confidence interval. Data are not given for
elevated PSA. ERSPC, European Randomized Study of Screening for Prostate Cancer
prostate specific antigen.a high proportion of 60 year olds with screen-detected
cancer following an elevated PSA will develop prostate
cancer that is detectable by symptoms over the course of
the subsequent 25 years, that is, the rate of overdiagnosis
is low.
Discussion
We analyzed population-based data on prostate cancer
incidence and found that an important majority of ex-
cess cases diagnosed in the first few years after the in-
troduction of PSA testing occurred in men older than
60. We then estimated the risk at age 60 for prostate
biopsy-detectable cancer in two different PSA-screened
population-based cohorts and compared this risk to that
of long-term metastasis and death from prostate cancer
in an unscreened population. The risk that a biopsy detec-
table cancer would not lead to cancer-related morbidity or
mortality increased exponentially as PSA fell below con-
ventional biopsy thresholds.
There are two major clinical implications of our find-
ings. First, more selective screening of men older than
60 is justified. We found that a clear majority of excess
cases are diagnosed in men older than 60, yet there is
randomized evidence from the European trial [2] that
screening reduces mortality for men in their 60s. As
such, it would appear unwise to recommend that screen-
ing be terminated at age 60 for all men. An alternative
would be to restrict screening to men with PSA levels
above 1 ng/ml (WHO calibration), close to the median.
Men with PSA <1 ng/ml – approximately 50% of the
population – can be told that if they continue to be
screened, any prostate cancer thereby detected is un-
likely to harm them and that if they elect to be treated
they will likely be subjecting themselves to overtreat-
ment. The ERSPC found evidence that screening is not
of benefit for men who start at age 70 or older, with thethe 25 year-risk of clinical prostate cancer endpoints
mortality Biopsy detected cancer (PCPT) Biopsy detected cancer
(ERSPC, Rotterdam)
.6) 12.2 (10.1, 14.6) -
.2) 10.1 (8.2, 11.7) -
.1) 16.9 (15.8, 18.2) -
.2) 21.5 (20.2, 23.0) -
.3) 22.2 (20.5, 23.9) 15.4 (8.1, 23.6)
.3) 23.2 (20.3, 25.4) 18.6 (16.3, 20.8)
.2) 23.5 (19.5, 26.5) 22.1 (20.3, 23.6)
5.9) 24.6 (16.8, 30.2) 29.8 (27.4, 31.6)
6.0) 25.6 (13.1, 33.9) 36.1 (32.9, 39.1)
(PCPT and ERSPC) by PSA level at age 60.
PSA <3 ng ml in the ERSPC cohort as biopsy was restricted to men with
; MPP, Malmo Preventive Program; PCPT, Prostate Cancer Prevention Trial; PSA,
Table 3 Relative risk of biopsy detected cancer compared to the 25 year-risk of clinical prostate cancer endpoints
PSA (ng/ml) PCPT (repeat screening) ERSPC, Rotterdam (initial PSA test)
Clinical
diagnosis
Distant
metastasis
Cancer-specific
mortality
Clinical
diagnosis
Distant
metastasis
Cancer-specific
mortality
<1.0 2.7 (1.9, 4.2) 21.6 (9.6, 69.5) 64.9 (18.2, 72.9) - - -
0.5 2.7 (1.8, 4.5) 38.0 (15.2, 192.3) 153.4 (48.2, 219.7) - - -
1.0 2.8 (2.3, 3.5) 14.5 (9.7, 27.2) 28.8 (15.4, 92.1) - - -
2.0 1.6 (1.5, 2.0) 4.7 (4.2, 6.1) 5.7 (5.1, 7.5) - - -
3.0 1.3 (1.1, 1.5) 3.4 (2.6, 4.0) 4.0 (3.0, 4.7) 0.9 (0.5, 1.4) 2.3 (1.2, 3.6) 2.8 (1.4, 4.2)
4.0 1.2 (0.8, 1.3) 2.7 (1.8, 3.2) 3.2 (2.0, 3.9) 0.9 (0.7, 1.1) 2.2 (1.5, 2.6) 2.6 (1.6, 3.1)
5.0 1.1 (0.7, 1.2) 2.3 (1.3, 2.8) 2.7 (1.5, 3.4) 1.0 (0.7, 1.1) 2.2 (1.3, 2.6) 2.6 (1.4, 3.1)
7.5 0.9 (0.4, 1.1) 1.7 (0.8, 2.1) 2.0 (0.8, 2.7) 1.1 (0.6, 1.3) 2.0 (1.1, 2.4) 2.4 (1.1, 3.0)
10.0 0.8 (0.3, 1.0) 1.3 (0.5, 1.8) 1.6 (0.5, 2.3) 1.1 (0.5, 1.3) 1.9 (1.0, 2.4) 2.3 (1.0, 2.9)
The data compare an unscreened Swedish cohort (MPP) with two screened cohorts (PCPT and ERSPC) by PSA level at age 60.
Data are given as percent risk with 95% confidence interval for two screened cohorts separately. Data are not given for PSA <3 ng/ml in the ERSPC cohort as
biopsy was restricted to men with elevated PSA. ERSPC, European Randomized Study of Screening for Prostate Cancer; PCPT, Prostate Cancer Prevention Trial;
PSA, prostate specific antigen.
Vickers et al. BMC Medicine Page 5 of 72014, 12:26
http://www.biomedcentral.com/1741-7015/12/26lower bound of the 95% CI excluding the central esti-
mate for risk reduction for men younger than 70 [2]; a
subsequent modeling study reported that any decreases
in mortality associated with screening men older than 70
were offset by overdiagnosis [13]. Restricting screening
in men in their 70s to a small group with excellent
health and above average PSA would likely reduce over-
diagnosis considerably without any substantive effect on
mortality.
The second implication of our findings is that it be-
comes hard to justify prostate biopsy in men with PSA
below typical thresholds for biopsy, such as 3 or 4 ng/ml.Figure 2 Risk of biopsy detectable cancer in a screened
population divided by the 25 year risk of death from prostate
cancer (solid black line), distant metastasis (solid grey line), and
clinical diagnosis of prostate cancer (dashed black line) in an
unscreened cohort, by PSA level at age 60. The dashed grey line
at a ratio of 1 is included as reference. Risk of biopsy detectable
cancer was obtained from the PCPT. The clinical endpoints were
obtained from the Malmö cohort. PCPT, Prostate Cancer Prevention
Trial; PSA, prostate specific antigen.It has been estimated that about one in seven diagnoses
occur in men with PSA below 4 ng/ml [14], constituting
about 35,000 cases a year. Although use of a lower PSA
threshold may be justifiable in younger men, such as those
below 50 years old, in clinical practice, older men with
low PSA are often subject to biopsy because of a positive
digital rectal exam, rapid increase in PSA, low ratio of
free-to-total PSA or family history [11,12]. Such indica-
tions would only be justified if they dramatically raised the
risk of aggressive cancer. There is no clear evidence that
this is the case.
Several lines of evidence from the literature support
our overall findings. First, the strong association between
overdiagnosis and age is supported by consideration of
life expectancy data. In the studies with appropriately
long follow-up, lead time has been estimated to average
around 12 years [15,16]. For instance, in the Malmö
cohort used for this paper, the mean time to clinical
diagnosis was 11.8 years among men who were subse-
quently diagnosed with cancer and who had a base-
line PSA ≥3 ng/ml at age 60 [15]. From the Social Security
Life Tables it can be calculated that the probability of
death within 12 years is 21% for a 60 year old but 45% for
a 70 year old. This means that, for a group of 200 men
with screen-detected cancer, half 60 years old and half
70 years old, 66 men would die before they would be ex-
pected to be clinically diagnosed. Of these, 45, close to
70%, would be in the older age group. These data can also
be used to support our finding that, in 60-year-old men
with PSAs above biopsy thresholds, most screen-detected
cancers would eventually lead to a clinical diagnosis, as
close to 80% of men survive longer than the mean lead
time. Moreover, the Malmö cohort does not stand alone
in finding that PSA is strongly predictive of prostate can-
cer mortality in unscreened populations. Numerous other
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and long-term prostate cancer outcomes [17-22].
PSA screening can only reduce mortality in that it
leads to curative treatment. Two trials have compared
surgery with conservative management for prostate cancer
[23,24] and both report a decreased effect of treatment
in older men. In one analysis [25], differences between
surgery and conservative treatment started to decrease
around age 65 with little benefit for men older than 70.
These studies indicate that the effects of treatment di-
minish with age, suggesting that men older than 70 should
only be considered for screening if they are at higher than
average risk for prostate cancer mortality and lower than
average risk for other cause mortality. Evidence that a risk
stratification approach, based on PSA, would improve
screening outcomes is provided by a reanalysis of the
ERSPC data. Van Leeuwen et al. evaluated the effects
of PSA-based screening on men in reference to the
PSA-level measured at their first screen. Their results
demonstrate that had men with a PSA <2 ng/ml at base-
line been excluded from further screening, the number of
men needing to be screened and diagnosed to prevent one
death would be reduced by 90% and 50%, respectively.
Results for a PSA cut-off of 1 ng/ml are not reported.
These findings are of particular relevance to our re-
commendations, as the median age in the screened group
was 61 [26].
One study using SEER data came to a quite different
conclusion from the current paper. Welch and Albertsen
reported that excess incidence ‘which must represent
overdiagnosis’ was ‘particularly dramatic for younger men’
[27]. There are two major problems with this conclusion.
First, it focuses on relative rather than absolute increase in
diagnoses. So, for example, the reported seven-fold in-
crease in men younger than 50 constitutes only 8 ad-
ditional cases per 100,000. A relative seven-fold increase
sounds large, suggesting that public health efforts might
focus on reducing screening in this age group, whereas
the absolute increase demonstrates that such efforts would
not have an important impact at the population level.
Second, the authors look at an extended period of PSA
screening, leading to age-related artifacts. For instance,
they state that in men older than 80, ‘incidence declined
dramatically between 1986 and 2005’. This is because
some men who would have been clinically diagnosed in
their 80s in the years 2000 to 2005 were screen-detected
at an earlier age. It would be entirely unsound to use this
finding to suggest that use of PSA in older men does not
lead to overdiagnosis.
It is worth considering differences both between the
different cohorts within the study and between these study
cohorts and contemporary patients. First, the biopsy co-
horts and the SEER population sample predominately
involved 6-core biopsy rather than the more extendedbiopsy schemes typical in current practice. This suggests
that we may have underestimated the risk of screen-
detected cancer. Second, prostate cancer mortality has
historically been higher in Sweden – around 5% of male
deaths compared to less than 3% in the US [28]. Moreover,
recent advances in treatment have led to improvements in
survival leading to a lower risk of death [29]. This suggests
that we may have overestimated the risk of death. The ef-
fect of any such misestimation – underestimating cancer
incidence, overestimating mortality risk − would be to ex-
acerbate the difference in risk by PSA levels: men with a
low PSA would be even more likely to have cancer de-
tected and even less likely to die without screening.
A clear limitation of our paper is that we are mea-
suring excess incidence, which is only a correlate of
overdiagnosis. Yet, overdiagnosis by its very nature is a
counterfactual – that a patient would die without a diag-
nosis if not for screen detection – and, therefore, cannot
be directly observed. Moreover, an increase in incidence,
even if only temporary, is a prerequisite of screening: a
screening test associated with zero overdiagnosis would
still raise incidence after clinical implementation, even
though incidence rates would subsequently fall below
prior levels. That said, a persisting increase in incidence,
as seen in the US, is clear evidence of overdiagnosis;
comparably, the gross disparities we have seen in the
relative number of excess cases by age clearly suggests
that restricting PSA screening in older men would im-
portantly shift overdiagnosis rates.
Conclusions
In conclusion, we provide evidence that correlates of
overdiagnosis are strongly related to age and PSA level.
Overdiagnosis appears to be predominately a problem of
older men and those with lower PSAs. The ratio of be-
nefits to harms for prostate cancer screening could be
improved by restricting screening in men older than 60
to those with PSA >1 ng/ml and restricting screening
in men older than 70 to those in excellent health and
higher PSA levels.
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